Perrigo upgraded by Argus with a new price target
$PRGO
Biotechnology: Pharmaceutical Preparations
Health Care
Argus upgraded Perrigo from Hold to Buy and set a new price target of $46.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/14/2025 | Buy → Hold | Argus | |
| 1/6/2025 | $34.00 → $27.00 | Overweight → Neutral | Piper Sandler |
| 9/24/2024 | $50.00 → $30.00 | Hold | Jefferies |
| 11/17/2023 | $37.00 | Overweight | Piper Sandler |
| 3/7/2023 | $49.00 | Buy | Canaccord Genuity |
| 9/14/2022 | $46.00 | Hold → Buy | Argus |
| 9/6/2022 | $48.00 → $54.00 | Equal Weight → Overweight | Wells Fargo |
| 11/11/2021 | $59.00 → $55.00 | Outperform | Raymond James |
4 - PERRIGO Co plc (0001585364) (Issuer)
4 - PERRIGO Co plc (0001585364) (Issuer)
4 - PERRIGO Co plc (0001585364) (Issuer)
SCHEDULE 13G/A - PERRIGO Co plc (0001585364) (Subject)
144 - PERRIGO Co plc (0001585364) (Subject)
8-K - PERRIGO Co plc (0001585364) (Filer)
For Immediate Release: July 13, 2023 Today, the U.S. Food and Drug Administration approved Opill (norgestrel) tablet for nonprescription use to prevent pregnancy— the first daily oral contraceptive approved for use in the U.S. without a prescription. Approval of this progestin-only oral contraceptive pill provides an option for consumers to purchase oral contraceptive medicine without a prescription at drug stor
Argus downgraded Perrigo from Buy to Hold
Piper Sandler downgraded Perrigo from Overweight to Neutral and set a new price target of $27.00 from $34.00 previously
Jefferies resumed coverage of Perrigo with a rating of Hold and set a new price target of $30.00 from $50.00 previously
Ron Janish, EVP Global Operations and Supply Chain, to Retire Industry Veteran, Matt Winterman, Appointed EVP Product Supply, Operations Strategy & Transformation Officer DUBLIN, June 4, 2025 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO), a leading global provider of Consumer Self-Care Products, today announced the appointment of Matt Winterman as Executive Vice President, Product Supply, Operations Strategy and Transformation Officer, effective June 23, 2025. Mr. Winterman succeeds Ron Janish, who will retire from the Company on September 30, 2025, following a distinguished career at Perrigo spanning more than two decades. Both executives will closely work together to ensure a smooth tran
DUBLIN, May 23, 2025 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO), a leading provider of Consumer Self-Care Products, today announced that President and CEO Patrick Lockwood-Taylor and CFO Eduardo Bezerra are scheduled to present at the Oppenheimer 25th Annual Consumer Growth & E-Commerce Conference, being conducted virtually on Tuesday, June 10 at 9 AM ET. Interested parties can access the webcast on the Perrigo website at http://perrigo.investorroom.com/events-webcasts. About Perrigo Perrigo Company plc is a leading pure-play self-care company with over a century of exper
Advancing 'Three-S' Plan to Stabilize, Streamline and Strengthen Perrigo, which was Detailed at February 2025 Investor Day Delivered Strong First Quarter 2025 Adjusted EPS Growth and Margin Expansion, Driven by Infant Formula and OTC Brands Widened 2025 Net Sales Target Ranges, Due Primarily to Macroeconomic Uncertainty; Reaffirmed All Other Previously Provided 2025 Financial Targets, Including Adj. EPS Range DUBLIN, May 7, 2025 /PRNewswire/ -- First Quarter 2025 Highlights: Net sales of $1.04 billion declined 3.5%, due primarily to an unfavorable impact of 3.2% from divested
4 - PERRIGO Co plc (0001585364) (Issuer)
4 - PERRIGO Co plc (0001585364) (Issuer)
4 - PERRIGO Co plc (0001585364) (Issuer)